Biogen Pharmachem Industries Ltd vs STATE BANK OF INDIA
A side-by-side comparison of Biogen Pharmachem Industries Ltd (BIOGENPHARMACHEMLTD) and STATE BANK OF INDIA (SBIN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, STATE BANK OF INDIA leads BIOGENPHARMACHEMLTD vs SBIN on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth10
- Size & financial health03
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SBIN takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
BIOGENPHARMACHEMLTD takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SBIN takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Stock is trading at 0.30 times its book value"]
- − ["Company has low interest coverage ratio.", "Company has a low return on equity of 1.11% over last 3 years."]
- + ["Company has been maintaining a healthy dividend payout of 18.6%"]
- − ["Company has low interest coverage ratio.", "Contingent liabilities of Rs.43,52,830 Cr.", "Company might be capitalizing the interest cost", "Earnings include an other income of Rs.1,99,967 Cr."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.